Company / R&D Expense
Vir Biotechnology, Inc. R&D Expense History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$456.0M
FY2025
5-year range
$148.5M / $579.7M
FY2021-FY2025
Trend
-10.0%
vs FY2024
Sector context
#36 of 210
Health Care
What the data says
Vir Biotechnology, Inc.'s r&d expense of $456M is higher than 83% of companies in the Health Care sector (FY2025). R&D Expense has fluctuated over the past 9 years, ranging from $63M in FY2017 to $580M in FY2023.
Based on SEC 10-K filings.
$456M in FY2025 with a 5-year CAGR of +8.6%. Top quartile in the Health Care sector.
Declined from $580M to $456M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +14.7%
- 5-Year CAGR
- +8.6%
- 10-Year CAGR
- -
Sector benchmark
Top 17% in Health CareTop 17% of 210This company $456.0M Sector average $644.1M
▼
-29.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +8.6%, indicating consistent growth.
- In FY2025, r&d expense decreased 10.0% year-over-year.
- Ranks #36 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $456.0M | -10.0% |
| FY2024 | $506.5M | -12.6% |
| FY2023 | $579.7M | +91.7% |
| FY2022 | $302.4M | +103.7% |
| FY2021 | $148.5M | -50.9% |
| FY2020 | $302.4M | +103.7% |
| FY2019 | $148.5M | +48.1% |
| FY2018 | $100.2M | +60.3% |
| FY2017 | $62.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026